University of California-Berkeley · BiochemistryTumor Immunology and Treg Dynamics Lab
Michel Dupage · Berkeley, California
Research Focus
Dr. Michel Dupage's lab focuses on understanding how regulatory T cells (Tregs) hinder the effectiveness of cancer immunotherapies. By studying the mechanisms through which Tregs suppress the immune response within tumors, the lab aims to develop targeted therapies that can enhance anti-tumor immunity while minimizing autoimmune side effects. This research is crucial for improving cancer treatment options and making immunotherapies more effective for patients.
regulatory T cellscancer immunotherapytumor immunosuppressionimmune responsedendritic cells
Research Aims
3AIM 01Investigate the mechanism of Treg control over dendritic cell antigen uptake.
AIM 02Determine how enhanced local antigen uptake in tumors can improve systemic immunity.
AIM 03Test the efficacy of intratumoral delivery of Treg-depleting antibodies for boosting anti-tumor immunity.
Skills the Lab Values
cell cultureflow cytometrymouse modelsin vitro assaysantibody injectiongene expression profilingPCRimmunofluorescencelymph node dissections
Output against the department
Publications59bottom 11% of dept.358th of 402
this lab
most publishedleast published
Citations5.6kbottom 32% of dept.272nd of 402
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.